Deals channel feed

Bay­er gets its hands on Acuitas' LNP as it lines up first shots at gene edit­ing

Last year
Cell/Gene Tx

No­vo Hold­ings, Gur­net Point Cap­i­tal en­gi­neer $462M take-pri­vate deal for an­tibi­otics play­er Paratek

Last year

Idor­sia notes po­ten­tial $440.8M Asia li­cens­ing deal to ex­tend cash run­way amid slow Qu­viviq sales

Last year

Am­gen con­tin­ues to tar­get mid-De­cem­ber dead­line for Hori­zon deal close

Last year
Pharma

No­vo Nordisk un­veils $165M buy­out bid for a drug de­liv­ery part­ner on smart in­sulin pens

Last year

Take­da ax­es gene ther­a­py deal with Po­sei­da Ther­a­peu­tics amid broad­er re­think

Last year
Cell/Gene Tx

Ger­man ra­dio­phar­ma biotech ac­quires British start­up in tiny deal

Last year

Roger Perl­mut­ter builds Eikon's pipeline with deal-mak­ing flur­ry, rais­ing $106M more

Last year
Financing

Lon­za shells out $107M cash to snap up Synaf­fix and its ADC plat­form

Last year
Manufacturing

Yuhan Cor­po­ra­tion to pay $325M to in-li­cense pre­clin­i­cal HER2 can­di­date

Last year
Pharma

MEI Phar­ma re­ceives un­so­licit­ed of­fer as it pro­ceeds with In­fin­i­ty merg­er

Last year

C4 Ther­a­peu­tics gets $35M from Bet­ta Phar­ma­ceu­ti­cals to de­vel­op and mar­ket NSCLC drug in Chi­na

Last year
R&D
China

XtalPi inks $250M pact with Lil­ly af­ter Pfiz­er suc­cess

Last year
China
AI

Atea's board re­jects un­so­licit­ed cash of­fer from Tang Cap­i­tal's Con­cen­tra

Last year
People

Mer­ck­'s $10.8B Prometheus buy­out can pro­ceed af­ter an­titrust re­view

Last year
Pharma

UCB en­ters gene ther­a­py space, ink­ing li­cense agree­ment for epilep­sy and neu­rode­gen­er­a­tion re­search

Last year
Cell/Gene Tx

Small SPAC to tiny sale: Apex­i­gen sprints to Pyx­is On­col­o­gy in $16M ex­it

Last year

Atea con­firms un­so­licit­ed cash pro­pos­al from Tang Cap­i­tal’s Con­cen­tra, the shell buy­ing Jounce Ther­a­peu­tics

Last year

Co­hBar, Mor­pho­gen­e­sis link up in re­verse merg­er of two can­cer biotechs

Last year
R&D

Who else want­ed to buy Iver­ic? Be­fore the $5.9B Astel­las deal, five bio­phar­ma com­pa­nies took a look

Last year
Pharma

Back Bay makes deal with Nor­way's DNB in bank­ing and ad­vi­so­ry part­ner­ship

Last year
Financing

No­var­tis beefs up gene ther­a­py pipeline, spend­ing $87.5M on an Avro­bio ther­a­py

Last year
Pharma
Cell/Gene Tx

Iron­wood to buy Vec­tivBio in $1B all-cash deal to ex­pand rare gas­troin­testi­nal pipeline 

Last year

Man­u­fac­tur­ing-cen­tric SPAC makes a deal to com­bine with French CD­MO

Last year
Manufacturing
First page Previous page 33343536373839 Next page Last page
A service from the Financial Times